Pulse Biosciences (Nasdaq:PLSE) today announced the enrollment of the first patient in its NANOCLAMP AF study for treating AFib. In September, the FDA granted investigational device exemption (IDE) for Pulse's nanosecond pulsed field ablation (nsPFA) system. Approval gave Pulse the green light to proceed with the initiation of the NANOCLAMP AF … [Read more...] about Pulse Biosciences enrolls first patient in NANOCLAMP PFA trial
Pulse Biosciences
Pulse Biosciences shares strong first-in-human PFA data
Pulse Biosciences (Nasdaq:PLSE) today announced clinical study results from a first-in-human study of its nPulse system. The company shared findings from the first-in-human feasibility study of the cardiac surgical system at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, Denmark. Pulse Biosciences' … [Read more...] about Pulse Biosciences shares strong first-in-human PFA data
Pulse Biosciences wins FDA IDE to conduct study of PFA tech for AFib
Pulse Biosciences (Nasdaq:PLSE) announced today that the FDA granted investigational device exemption (IDE) for its pulsed field ablation (PFA) system. The approval allows Pulse to proceed with the initiation of the NANOCLAMP AF study. NANOCLAMP AF evaluates the company's nanosecond PFA (nsPFA) Cardiac Surgery System for treating AFib. According … [Read more...] about Pulse Biosciences wins FDA IDE to conduct study of PFA tech for AFib
Pulse Biosciences reports first-in-human data for PFA to treat benign thyroid nodules
Pulse Biosciences (Nasdaq:PLSE) today announced the publication of first-in-human feasibility study results for its pulsed field ablation (PFA) technology. Dr. Stefano Spiezia conducted the study at the Ospedale del Mare Center in Naples, Italy. It evaluated the effectiveness of the company's nanosecond pulsed field ablation (nsPFA) in benign … [Read more...] about Pulse Biosciences reports first-in-human data for PFA to treat benign thyroid nodules
Pulse Biosciences is on track for IDE study of PFA tech this year
Pulse Biosciences (Nasdaq:PLSE) today announced feasibility study data supporting its Nanosecond PFA 360° cardiac catheter system. Along with the data, Paul LaViolette, the company's new CEO and co-chair, said Pulse Biosciences remains on track to begin an FDA investigational device exemption study this year. “[We] look forward to continuing … [Read more...] about Pulse Biosciences is on track for IDE study of PFA tech this year
Pulse Biosciences announces first human use of pulsed-field ablation catheter
Pulse Biosciences (Nasdaq:PLSE) today announced the completion of the first-in-human procedures for its CellFX nsPFA cardiac catheter. The Hayward, California-based company completed the first five procedures in its first-in-human feasibility study. Treating physicians successfully discharged all patients. They'll continue to be monitored and … [Read more...] about Pulse Biosciences announces first human use of pulsed-field ablation catheter
Pulse Biosciences, CardioNXT to collab on pulsed-field ablation trial
Pulse Biosciences (Nasdaq:PLSE) announced today that it entered into a collaboration with CardioNXT to support its AFib treatment. The collaboration supports Pulse Biosciences' planned first-in-human study of its pulsed-field ablation technology. Hayward, California-based Pulse develops a proprietary nanosecond pulsed-field ablation (nsPFA) … [Read more...] about Pulse Biosciences, CardioNXT to collab on pulsed-field ablation trial
